Hims & Hers Stops Semaglutide Weight-Loss Sales After FDA Scrutiny
Hims & Hers will cease offering its semaglutide-based weight-loss treatment after regulators raised concerns over its marketing and prescription processes, eliminating a lower-cost alternative to Wegovy. The withdrawal secures Novo Nordisk’s market position in the U.S. obesity therapy segment by preserving Wegovy’s pricing and share.
1. Hims & Hers Discontinues Semaglutide Offering
Hims & Hers announced an immediate halt to its semaglutide-based weight-loss product following regulatory scrutiny of its telemedicine marketing and prescription protocols. The company will remove the treatment from its platform and notify existing patients of alternative options.
2. Impact on Novo Nordisk’s Wegovy
With Hims & Hers’ lower-priced rival off the market, Wegovy faces reduced competitive pressure, helping Novo Nordisk maintain its pricing power and sales volume in the U.S. obesity treatment market. Analysts expect this could bolster Novo Nordisk’s quarterly prescription growth rates.
3. Regulatory Environment and Industry Implications
Heightened oversight of direct-to-consumer telehealth services may deter smaller players from launching copycat GLP-1 therapies. The move underscores barriers to entry in obesity treatment, reinforcing dominance by established biotech leaders with robust regulatory compliance infrastructures.